- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01109290
Characterization of Sweat Gland Function in Patients With Recessively Inherited Hypohidrotic Ectodermal Dysplasia
September 13, 2011 updated by: Prof. Dr. Holm Schneider, University Hospital Erlangen
Validation of Non-invasive Technologies for the Characterization of Sweat Gland Function in Patients With Recessively Inherited Hypohidrotic Ectodermal Dysplasia, Their Heterozygous Family Members and Healthy Controls
Hypohidrotic ectodermal dysplasia (HED) is a complex genetic disorder characterized by lack of sweat glands, sparse hair, and missing or malformed teeth.
Inability to sweat may result in episodes of severe hyperthermia and cause sudden infant death.
To assess sweat gland function in HED patients, the investigators will first quantify gland pores in a defined area of the palm and then stimulate the glands by pilocarpine followed by sweat collection in a special capillary for volume determination.
This will be combined with non-invasive skin conductance measurement prior and subsequent to stimulation of the sympathetic nervous system.
The data should provide a basis for genotype-phenotype correlation.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
65
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Bavaria
-
Erlangen, Bavaria, Germany, D-91054
- University Hospital Erlangen
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 60 years (ADULT, CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
subjects with recessively inherited hypohidrotic ectodermal dysplasia (HED), their heterozygous family members and healthy controls
Description
Inclusion Criteria:
- for patients: hypohidrotic ectodermal dysplasia caused by mutations in the genes EDA or EDAR
- written informed consent
Exclusion Criteria:
- febrile disease
- pregnancy or breastfeeding
- implantable electronic devices, e.g. pacemaker
- hypersensitivity to self-adhesive electrodes
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
HED children
|
Control children
|
HED adults
|
Control adults
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2010
Primary Completion (ACTUAL)
August 1, 2010
Study Completion (ACTUAL)
June 1, 2011
Study Registration Dates
First Submitted
April 21, 2010
First Submitted That Met QC Criteria
April 22, 2010
First Posted (ESTIMATE)
April 23, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
September 14, 2011
Last Update Submitted That Met QC Criteria
September 13, 2011
Last Verified
September 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ED10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypohidrotic Ectodermal Dysplasia
-
Edimer PharmaceuticalsCompletedX-linked Hypohidrotic Ectodermal DysplasiaUnited States
-
Edimer PharmaceuticalsActive, not recruitingX-linked Hypohidrotic Ectodermal DysplasiaUnited States, United Kingdom, France, Germany, Italy
-
University Hospital ErlangenEdimer PharmaceuticalsCompletedX-linked Hypohidrotic Ectodermal DysplasiaGermany
-
Edimer PharmaceuticalsCompletedX Linked Hypohidrotic Ectodermal DysplasiaUnited States
-
EspeRare FoundationIqvia Pty Ltd; Pierre Fabre MedicamentRecruitingX-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)United States, Spain, France, Germany, Italy, United Kingdom
-
Edimer PharmaceuticalsCompletedX-linked Hypohidrotic Ectodermal Dysplasia | Hypohidrotic Ectodermal DysplasiaUnited States
-
Edimer PharmaceuticalsCompletedX-linked Hypohidrotic Ectodermal Dysplasia | Hypohidrotic Ectodermal DysplasiaSpain
-
Edimer PharmaceuticalsCompletedX-Linked Hypohidrotic Ectodermal DysplasiaUnited States, United Kingdom, France, Germany, Italy
-
Edimer PharmaceuticalsCompleted
-
Edimer PharmaceuticalsCompletedX-Linked Hypohidrotic Ectodermal DysplasiaUnited States, United Kingdom, France, Germany, Italy